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Phosphate deprivation increases serum 1 ,25-(OH)2-vitamin D
concentrations in healthy men
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Phosphate deprivation increases serum 1,25.(OH)2-vitamin D concen-
trations in healthy men. To re-evaluate whether phosphate-deprivation
alters serum 1 ,25-(OH)2-D concentrations in men, we measured serum
1,25-(OH)2-D levels in seven healthy men while they ate constant diets
providing 52.2 4.3 SD mmoles P04/day for 12 days and then while
they ate a diet providing 29.4 6.0 mmoles P04/day and also were
given Al(OH)3 for 18 days. Serum P04 levels fell only transiently. Net
intestinal P04 absorption became indistinguishable from zero but,
because of renal P04 conservation, P04 balances did not change.
Nevertheless, serum I ,25-(OH)2-D concentrations increased from 80
21 M during control to 104 26 pM; during P04 deprivation; P < 0.01.
Net intestinal calcium (Ca) absorption tended to rise during P04
deprivation, the individual increments being correlated to the incre-
ments in serum l,25-(OH)2-D concentrations (r = 0.78; P < 0.05).
Urinary Ca excretion rose; P < 0.001, the increments exceeding the
increments in net intestinal Ca absorption so that Ca balances became
more negative; P < 0.001. Urinary hydroxyproline excretion did not
change. Thus, as in women and animals, PU4 deprivation appears to
cause enhanced net bone resorption apparently by reducing bone
formation.
La restriction phosphatée augmente les concentrations de 1 ,25-(OH)2-
vitamine D sérique chez I'homme normal Afin de réévaluer si Ia
restriction en phosphate altère les concentrations sériques de 1,25-
(OH)2D chez l'homme, nous avons mesurC les niveaux seriques de 1,25-
(OH)2D chez sept hommes sains, alors qu'ils consommaient des ré-
gimes constants apportant 52,2 4,3 SD mmoles P04/jour pendant 12
jours et pendant qu'ils consommaient un régime apportant 29,4 6,0
mmoles P04 par jour, en méme temps qu'ils recevaient de I'Al(OH)3
pendant 18 jours. Les niveaux de P04 se sont abaissés seulement
transitoirement. L'absorption intestinale de P04 est devenue non
différente de zero, mais en raison de la conservation rénale du P04, la
balance de P04 n'a pas change. Cependant, les concentrations seriques
de l,25-(OH)2D se sont élevées de 80 21 M pendant le contrôle a 104
26 M pendant Ia restriction en P04: P < 0.01. L'absorption
intestinale nette de calcium (Ca) avait tendance a s'élever pendant Ia
restriction en P04, les augmentations individuelles étant corrélées avec
les augmentations des concentrations de I ,25-(OH)2D sérique (r = 0.78,
P < 0.05). L'excrétion urinaire de Ca s'est élevée; P < 0.001, les
augmentations dépassant les augmentations de l'absorption intestinale
nette de Ca, de sorte que les balances de Ca sont devenues plus
negatives; P < 0.001. L'excrétion urinaire d'hydroxyproline n'a pas
change. Ainsi, de même que chez les femmes et chez les animaux, Ia
restriction en P04 paraIt entraIner une stimulation de la resorption
osseuse nette, apparemment en réduisant Ia formation d'os.
Plasma concentrations of 1,25-dihydroxyvitamin D (1,25-
(OH)2-D) increase when animals of either sex are deprived of
dietary phosphate, reflecting increased renal synthesis of this
hormone [1—3]. We previously observed that the disappearance
of injected 3H-25-OH-D from the plasma was accelerated when
healthy women and men were deprived of dietary phosphate
using liquid formula diets, implying increased synthesis of 1,25-
(OH)2-D [4]. Furthermore, women exhibited a rise in plasma
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1 ,25-(OH)2-D concentrations in those studies accompanying a
fall in serum phosphate concentrations [5]. However, we did
not observe a change in plasma l,25-(OH)2-D or phosphate
concentrations among the men. In addition, the control mea-
surements of plasma 1 ,25-(OH)2-D levels among the men in
those studies were made after they had resumed eating a normal
whole food diet. We subsequently recognized that this defect in
study design might have obscured an increase in plasma levels
of the hormone, since the ingestion of liquid diets containing
normal amounts of phosphate and other minerals is accompa-
nied by a fall in plasma 1,25-(OH)2-D levels [6]. Thus, the
present studies were undertaken to reevaluate the effects of
dietary phosphate deprivation on plasma 1 ,25-(OH)2-D concen-
trations in healthy men.
Methods
Seven healthy men ranging in age from 19 to 36 years were
studied with their consent in the Medical College of Wisconsin
Clinical Research Center, Milwaukee, Wisconsin, under a
protocol approved by the Medical College of Wisconsin Human
Research Review Committee.
The overall study sequence included 4 days of adaptation to
the control diet, a 6-day control balance period and 2 additional
days to permit passage of the carmine used to demarcate the
stool periods. The control period was then immediately fol-
lowed by three 6-day balance periods of phosphate deprivation
achieved by a reduction in dietary phosphate intake and by the
continuous oral administration of Al(OH)3 to limit intestinal
phosphate absorption. A terminal 2-day period on the same
regime was used to permit passage of the final carmine stool
marker. One subject, number 5, was studied only during two
periods of reduced P04 intake and Al(OH)3 administration.
Each subject ate a constant diet throughout his study. The diets
provided, by calculation, an average of 3000 200 kcallday, 9%
as protein, 32% as fat, and 59% as carbohydrate. They did not
contain gelatin. The basic diets contained, by analysis of
duplicates, an average of 26.9 5.6 mmoles P04/day, 5.4 1.2
mmoles Ca/day and 11.3 3.3 mmoles Mg/day. These diets
contained less than normal amounts of phosphate, calcium, and
magnesium. Thus, in addition, during the adaptation and the
control periods, each subject ate a total of five or six cookies in
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divided amounts with meals each day that provided supplemen-
tary phosphate as a 4:1 mixture of Na2HPO4 and NaH2PO4
(25.3 1.7 mmoles/day), calcium, as Ca(OH)2 (15.1 0.6
mmoles/day), and magnesium, as Mg(OH)2 (8.3 1.0 mmoles/
day). During the experimental periods each subject ate five or
six cookies which contained similar quantities of calcium and
magnesium but only 2.4 0.1 mmoles phosphate/day together
with A1(OH)3 (two subjects 115 mmoles/day, three subjects 165
mmoles/day and two subjects 180 mmoles/day).
The doses of A1(OH)3 varied because we initially chose to use
115 mmoles/day, approximately the lowest dose observed by
Spencer et al [7] to completely inhibit intestinal P04 absorption.
When we found that such a dose failed to cause negative P04
balances or sustained hypophosphatemia, we empirically in-
creased the doses for the subjects studied subsequently.
Twenty-four hour urine samples were collected and, in
addition, fasting morning urine specimens were collected on
one control morning and on one morning during the second and
during the third 6-day Al(OH)3 periods. Fasting morning blood
specimens were obtained on 3 or 4 control days and 6 to 9 days
during Al(OH)3.
The methods employed for the measurement of phosphate,
calcium, and magnesium in serum, urine, diets and feces have
been reported previously [8]. 25-OH-D and 1 ,25-(OH)2-D were
measured by competitive protein binding assay [9, 10]. During
the period of time over which these studies were carried out,
the interassay coefficient of variation for the measurement of
1,25-(OH)2-D in a human plasma pool averaged 19% (N = 18)
and recovery of l,25-(OH)2-D from a human plasma pool
averaged 103 22% (N 8). Serum PTH was measured as
previously reported using antibody kindly provided by Dr.
Eduardo Slatopolsky, Washington University School of Medi-
cine, St. Louis, Missouri [111. Urinary hydroxyproline was
measured on 2 control days and on 2 days during the final 6-day
Al(OH)3 period [12].
The results are presented as either individual data for each
subject or averages for individual subjects during control and
during Al(OH)3 or as the means of these averages for the group
SD. Changes were evaluated by two-way analysis of variance
and the individual changes from control for the group by
Student's t test for paired data [13]. Linear correlations were
calculated by least squares.
Results
Control conditions. During the control periods, as shown in
detail in Table 1, fasting serum phosphate and 1 ,25-(OH)2-D
levels were normal and stable although there was, as expected,
considerable variation among the subjects [14—25]. The concen-
trations of other measured serum constituents were also normal
(Table 2). Average body weight did not change for the group
and daily phosphate, calcium, and magnesium balances were
stable and not significantly different from zero (Table 3).
Fasting urine composition and daily urinary hydroxyproline
excretion were also normal (Table 4).
Effects of dietary P04 reduction and Al(OH)3 administration
Phosphate. When dietary P04 intake was reduced and
Al(OH)3 administration begun, fecal P04 excretion rose. As a
consequence and as expected [7, 26], net intestinal P04 absorp-
tion was not different from zero during Al(OH)3 administration.
Table 1. Fasting serum P04 and I ,25-(OH)2-D concentrations
Control day
Control
mean1 3 5 7
Serum P04, mM
Subject 1 1.45 1.58 1.50 1.61 1.54
2 1.53 1.42 1.58 1.56 1.52
3 1.15 — 1.24 1.21 1.20
4 1.16 — 1.13 1.34 1.21
5 1.23 — 1.27 1.31 1.27
6 1.06 1,32 1.19 1.42 1.25
7 1.44 1.42 1.37 1.58 1.45
Group mean 1.29 1.44 1.33 1.43 1.35
SDp
Serum l,25-(OH)2-D, M
Subject 1 85 97 106 99 97
2 62 48 37 50 49
3 104 126 — 88 106
4 77 81 — 79 79
5 93 94 — 92 93
6 50 72 69 36 57
7 122 72 68 67 82
Group mean 84 67 70 70 80
5D
pa
The probability that the mean of the individual changes from control
is not different from zero as determined by two-way analysis of
variance.
Urinary P04 excretion fell promptly by day 3 of Al(OH)3
administration to levels averaging 3.5 2.4 mmoles/day. De-
spite the augmentation of fecal PD4 excretion during Al(OH)3
administration, average daily PU4 balances were not different
from those observed during control when the data for the
second and third 6-day Al(OH)3 periods were evaluated (Table
3). We chose to compare only these two latter periods, since
fecal and urinary P04 excretion rates were changing during the
first 6-day period of Al(OH)3 administration. Average serum
P04 levels were significantly lower than control on days 3 and 5
of Al(OH)3 administration but thereafter did not differ from
control (Table 1).
Serum 1,25-(OH)2-D. As shown in Table 1, serum 1,25-
(OH)2-D concentrations rose during the administration of
Al(OH)3, reaching levels significantly above control by day 7
and remaining relatively stable thereafter. During days 7 to 19
of Al(OFI)3 administration, the increase averaged +24 15 pM;
(P < 0.01); Table 1) or +32 21% of individual control values
(P < 0.01).
Although we previously observed a significant inverse rela-
tionship between serum l,25-(DH)2-D and serum P04 levels [5],
such a relationship was not apparent in the present studies since
serum P04 levels were not different from control levels during
the later phases of Al(OH)3 administration when serum 1,25-
(OH)2-D levels remained elevated (Table 1).
Calcium. As shown in Table 3, dietary Ca intake was slightly
higher during Al(OH)3 administration, averaging + 1.4 0.3
mmoles/day more than during control (P < 0.001); the increase
apparently was the result of small changes in the composition of
the cookies. Al(OH)3 administration had no detectable effect on
average daily fecal Ca excretion or net intestinal Ca absorption
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Table 1. (Continued)
Day of dietary P04 reduction and A1(OH)3 administration
Mean for
days 7to 193 5 7 9 11 13 15 17 19
1.39 1.47 1.61 1.45 1.63 1.66 — 1.56 1.47 1.56
1.35 1.48 1.48 1.61 1.66 — 1.58 1.65 1.58 1.59
1.19 1.10 1.06 0.97 1.10 1.19 1.44 1.11 1.26 1.18
1.19 1.00 1.40 1.23 1.40 1.24 1.31 1.35 1.39 1.32
1.10 1.23 1.27 1.19 1.02 1.10 — — — 1.14
0.90 0.84 1.06 1.06 — 1.15 1.16 0.97 1.19 1.10
1.29 1.31 1.27 1.42 1.42 — 1.40 1.39 1.55 1.41
1.20 1.20 1.31 1.28 1.37 1.27 1.38 1.34 1.41 1.33
±0.17 ±0.24 ±0.21 ±0.23 ±0.26 ±0.23 ±0.16 ±0.26 ±0.16 ±0.20
<0.01 <0.01 NS NS NS NS NS NS NS NS
74 72 114 85 78 — — 119 119 103
82 108 60 79 61 — 77 65 90 72
103 181 160 190 139 160 159 152 136 156
73 105 120 126 80 100 84 69 71 93
101 117 121 118 94 116 — — — 112
79 90 88 117 — 78 117 76 91 94
53 98 66 120 121 — 97 91 93 98
81 110 104 119 96 114 107 95 100 104
±17 ±34 ±35 ±36 ±29 ±35 ±33 ±34 ±23 ±26
NS NS <0.01 < 0.01 NS < 0.01 <0.01 NS < 0.05 <0.001
Table 2. Mean serum composition
Control
A1(OH)3 days
7 to 18 pa
Ca, mi 2.38 ± 0.12k' 2.42 ± 0.08 +0.04 ± 0.05 NS
Mg, msi 0.90 ± 0.08 0.86 ± 0.07 —0.04 ± 0.03 <0.05
25-OH-D, nM 53 ± 10 51 ± 14 —2 ± 8 NS
iPl'H, a1EqIm1 7.5 ± 2.9 6.7 ± 3.2 —0.7 ± 0.8 NS
Serum creati-
nine, p.M 103 ± 14 104 ± 13 +1 ± 5 NS
a The probability that the mean of the changes from control is not
different from zero.
b Mean ± SD.
for the group (Table 3). However, the individual changes from
control for percent intestinal Ca absorption (diet Ca minus fecal
Ca x 100 divided by diet Ca) were significantly correlated to the
individual changes from control of serum 1 ,25-(OH)2-D concen-
trations: A Percent intestinal Ca absorption = —5.4 + 0.44 A
serum l,25-(OH)2-D, pt; r = 0.81, P < 0.05.
Urinary Ca excretion rose significantly by day 2 of Al(OH)3
administration, reaching sustained levels averaging 2.7 ± 1.2
mmoles/day above control by day 4 (P < 0.001). Since net
intestinal Ca absorption for the group did not change during
Al(OH)3 administration while urinary Ca excretion rose, daily
Ca balances became significantly more negative (Table 3).
Magnesium. As shown in Table 3 neither dietary Mg intake
nor fecal Mg excretion changed during Al(OH)3 administration.
However, urinary Mg excretion rose slightly but significantly
(Table 3), despite which Mg balances did not change. Serum Mg
fell slightly but significantly (Table 1) as we observed previous-
ly during P04-deprivation [4].
Daily urinary hydroxyproline excretion and fasting urine
composition
As shown in Table 4, average daily urinary hydroxyproline
excretion did not change during Al(OH)3 administration. Table
4 also shows that fasting urinary P04/creatinine fell significantly
as expected. Although daily urinary Ca excretion increased
(Table 3), the small increase in fasting urinary Ca/creatinine was
not statistically significant. Similarly, fasting urinary Mg/crea-
tinine did not change during Al(OH)3 administration despite the
significant increase in daily urinary Mg excretion.
Discussion
The present studies show that modest P04 deprivation in
healthy men, produced by a reduction in dietary P04 intake and
the administration of Al(OH)3, does result in an approximate
30% increase in the serum concentrations of 1 ,25-(OH)2-D. This
increase occurred despite the lack of a sustained decrease in
serum P04 concentration or detectably more negative P04
balances. Clearly, our ability to detect such a small but signifi-
cant increase in the plasma level of this hormone depended on
both the availability of multiple measurements during both the
control and the Al(OH)3 study periods (which minimized the
well known analytical variability of the difficult assay for 1,25-
(OH)2-D) as well as the use of paired observations in each
subject.
Recently, other investigators have shown that serum 1,25-
(OH)2-D levels rise by about 30 to 50% when healthy men are
deprived of dietary P04 and given Al(OH)3 for periods of 4 to 10
days [27, 28]. During these shorter studies serum P04 levels fell
slightly but significantly as we observed during the initial week
of Al(OH)3 administration.
The increase in serum 1 ,25-(OH)2-D concentrations in re-
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weight, kg 74.1 7.8b 73.4 7.3
Final body weight,
kg 73.5 7.7 73.0 7.2
Average weight
change, kg —0.6 0.6 —0.4 0.7
P04, mmoleslday
Diet 52.2 4.3 29.4 6.0 —22.8 2.4 <0.001
Feces 20.3 3.2 26.7 3.6 +6.4 2.6 <0.001
Net intestinal
absorption 31.9 3.9 2.7 3.5 —29.2 3.7 <0.001
Urine 31.8 2.5 3.5 2.4 —28.3 3.5 < 0.001
Balance +0.1 6.1 —0.8 2.0 —0.9 4.9 NS
Calcium, mmo!esl
day
Diet 20.5 1.6 21.9 1.4 +1.4 0.3 < 0.001
Feces 18.9 1.4 19.1 0.8 +0.2 1.5 NS
Net intestinal
absorption 1.6 2.2 2.8 1.0 +1.2 1.6 NS
Urine 3.7 1.2 6.4 2.1 +2.7 1.2 < 0.001
Balance —2.1 2.9 —3.6 2.7 —1.5 0.8 < 0.001
Magnesium,
mmoleslday
Diet 19.7 2.6 19.4 2.7 —0.3 0.7 NS
Feces 14.5 3.2 14.4 3.6 —0.1 2.8 NS
Net intestinal
absorption 5.2 2.2 5.0 1.6 —0.2 2.5 NS
Urine 4.9 0.8 5.8 1.0 +0.9 0.7 <0.025
Balance +0.3 2.2 —0.8 1.1 —1.1 2.3 NS
'The probability that the mean of the changes from control is not
different from zero.
bMean 50.
sponse to P04 deprivation in the present studies is consistent
with our previous observations of accelerated disappearance of
radiolabelled 25-OH-D3 from the plasma (implying increased
conversion to 1 ,25-(0H)2-D3) when healthy men ate a liquid diet
providing an average of only 2.8 mmoles P04/day and among
whom morning fasting serum P04 concentrations also did not
change from control levels [4]. Although we previously were
unable to detect an increase in plasma 1 ,25-(OH)2-D levels
among those men [51, it now seems likely that our failure to
detect an increase was the result of at least two difficulties: (1)
the availability of only single control and experimental mea-
surements and (2) the fact that the control measurements were
obtained after those men had resumed eating a normal whole
food diet rather than a liquid diet containing P04 since the
ingestion of such liquid diets can reduce serum 1 ,25-(OH)2-D
concentrations [61.
The present studies unfortunately do not provide any new
insight into the precise mechanism by which P04 deprivation
raises serum 1,25-(OH)2-D levels. It seems likely that the
increase in serum 1 ,25-(OH)2-D is the consequence of increased
renal synthesis of the hormone because of the rapid clearance of
l,25-(OH)2-D in normal humans [29, 301 and because P04
deprivation in vitamin D-replete rats increases the in vitro
synthesis of 1,25-(OH)2-D3 by kidney cortical slices [311 and
kidney homogenates [32]. The stimulus for such increased
synthesis of 1 ,25-(OH)2-D appears to require at least a transient
fall in fasting serum P04 concentrations and perhaps a sustained
Table 4. Average daily urinary hydroxyproline excretion and fasting
urine composition
Control Al(OH)3 A Pa
Urinary hydroxypro-
line, jmo1esIday 0.30 0.11" 0.31 0.09 +0.01 0.06 NS
Fasting urine PU4,
mmoles/mmoles
creatinine 0.93 0.39 0.26 0.27 —0.67 0.46 <0.01
Fasting urine Ca,
mmoleslmmoles
creatinine 0.15 0.06 0.22 0.10 +0.07 0.08 NS
Fasting urine Mg,
mmoles/mmoles
creatinine 0.26 0.13 0.27 0.09 +0.01 0.10 NS
The probability that the mean of the changes from control is not
different from zero.
"Mean SD.
decrease that might have been detectable had we obtained
multiple measurements of serum P04 concentrations through-
out the day during both the control and Al(OH)3 study periods.
Among healthy women, a sustained decrease in fasting serum
P04 concentrations is detectable during dietary P04 deprivation
which is accompanied by increased plasma l,25-(OH)2-D con-
centrations [5]. Also, plasma I ,25-(OH)2-D concentrations rise
within 2 days, as plasma P04 levels fall when rats of either sex
are deprived of dietary P04 [31. However, during these brief
periods, the decrease in plasma P04 concentrations is not
accompanied by a detectable decrease in kidney cortical phos-
phate content [331. However, others have found subtle decre-
ments in intracellular nucleoside triphosphate concentrations
after longer periods of phosphate deprivation [34]. Clearly
changes in these or other small cellular phosphate pools may
provide the signal for activation of l,25-(OH)2-D synthesis.
Despite our inability to detect more negative P04 balances
during Al(OH)3 administration, Ca balances did become more
negative (Table 3). Presumably, P04 balances would have
become significantly negative had the studies been prolonged or
the doses of Al(OH)3 increased [7, 261. It seems reasonable to
conclude that the more negative Ca balances that developed
during P04 deprivation reflected increased net bone resorption.
In turn, this effect would likely be the result of inhibition of
bone formation since urinary hydroxyproline excretion did not
change (Table 4). Such an effect may be the result of either
phosphate deprivation [35] or perhaps aluminum itself [36, 37].
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